Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial).
Kiyotaka OkunoToru AoyamaKoji ObaNoboru YokoyamaNobuhisa MatsuhashiKatsuyuki KuniedaYoji NishimuraHiroki AkamatsuTakaya KobatakeSatoshi MoritaTakaki YoshikawaJunichi SakamotoShigetoyo SajiPublished in: Cancer chemotherapy and pharmacology (2017)
The present study suggests that UFT and PSK are not attractive candidates to advance to the next phase III study because the DFS was slightly worse in the UFT and PSK arm than in the surgery-alone arm.